An international task force has updated recommendations for axial and peripheral spondyloarthritis, and psoriatic arthritis, which include treat-to-target recommendations…
(Reuters Health)—More than two-thirds of surgery patients in a recent study had prescription opioids left over after they recovered from their operations, and the vast majority failed to safely store or dispose of the often misused and abused pills, researchers say. “Unused opioids that have been prescribed for pain after surgery serve as an important…
The landscape of practice management and coding methodologies continues to be challenging in the current healthcare environment, and rheumatology practices must maintain focus on managing an effective and efficient practice. Join us at the 2017 ACR/ARHP Annual Meeting, Nov. 3–8 in San Diego, and gain knowledge and understanding of best practices in an ever-changing environment…
A new tool for assessing the risk of developing knee osteoarthritis (OA) may be useful for knee OA education. A recent study found the online risk calculator, OA Risk C, was effective in helping patients better understand their personal risk of developing the disease. It may also motivate some patients to embrace exercise-related behavior changes…
The FDA has approved abatacept to treat adults with active psoriatic arthritis. In clinical trials, the treatment has proved effective in both intravenous and subcutaneous forms…
A 2017 survey showed that rheumatologists’ pay has plateaued. And according to Anne Bass, MD, many cognitive fields, such as pediatrics and endocrinology, remain underpaid due to the current reimbursement structure…
The AMA House of Delegates (HOD) met in Chicago for its annual meeting June 9–14. More than 530 HOD members were present, with several hundred AMA and association staff and guests. As I am sure you have noted from past issues of ACR@Work, the ACR is in its five-year membership review. The ACR must be…
Researchers may have established a relationship between a new RA autoantibody, anti-carbamylated protein (anti-CarP) antibodies, and increased mortality risk. The recent study showed that anti-CarP was the only autoantibody associated with mortality, specifically respiratory system cause of death…
Romosozumab’s Future Is Uncertain Romosozumab, which has the possible U.S. brand name Evenity, is awaiting approval from the FDA.1 The treatment is an investigational, injectable biologic for treating osteoporosis. It increases bone formation and bone density, reducing a patient’s risk of fractures. The manufacturer no longer expects the FDA to approve the drug this year…
WASHINGTON (Reuters)—The collapse of Republicans’ push to repeal and replace Obamacare in the U.S. Senate set up a possible repeal-only vote and clouded the path forward for President Donald Trump’s other domestic policy goals, rattling financial markets on Tuesday. After two Republicans said they would not back the latest Obamacare rollback bill, Senate Majority Leader…